Apothecon Pharmaceuticals is a contract manufacturer based in India. It appears in 4 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with MINSA (CR), NCELS (KZ) and EDE (AE). Its GMP standing is certified by CDSCO (India), MFDS (Korea) and EMA, among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 27 January 2023 as VAI. Customs aggregates show $9.7M of exports covering 152 molecules to 21 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Vadodara, United Arab Emirates | Not on file |
| Vadodara, India | 3008405956 |
| GUJARAT, India | Not on file |
| anand, India | Not on file |
| tal padravadodara, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Benzatropine | SFDA (Saudi Arabia) | 1 |
| Benzoic Acid | SFDA (Saudi Arabia) | 1 |
| Carglumic Acid | SFDA (Saudi Arabia) | 1 |
| Carmustine | SFDA (Saudi Arabia) | 1 |
| Fomepizole | SFDA (Saudi Arabia) | 1 |
| Penicillamine | SFDA (Saudi Arabia) | 1 |
| Sevelamer Carbonate | SFDA (Saudi Arabia) | 1 |
| Sodium Bicarbonate | SFDA (Saudi Arabia) | 1 |
| Triethylenetetramine | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 2 | None |
| NCELS (KZ) | 1 | None |
| EDE (AE) | 1 | None |
| CDSCO (India) | None | 4 |
| MFDS (Korea) | None | 2 |
| EMA | None | 2 |
| ANVISA (Brazil) | None | 1 |
| MHRA (UK) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $392K | 7 |
| 2025 | Not reported | $9.7M | 21 |
| 2024 | Not reported | $5.3M | 17 |
| 2023 | Not reported | $3.2M | 24 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Apothecon Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free